New cholera vaccine trial aims to protect south africans of all ages

NCT ID NCT07304284

Recruiting now ⭐️ VACCINE ⭐️ Sponsor: International Vaccine Institute Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new oral cholera vaccine (Biovac OCV-S) to see if it works as well as a currently approved vaccine (Euvichol-Plus). About 2,824 healthy people aged 1 to 45, including some adults living with HIV, will receive two doses. Researchers will check immune responses and monitor for side effects over several months.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHOLERA VACCINATION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

HIV infectious disease cholera prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHOLERA VACCINATION

Contacts and locations

Locations

Perinatal HIV Research Unit (PHRU)
RECRUITING

Johannesburg, Gauteng, 1862, South Africa
SAMRC Chatworth CRS
RECRUITING

Durban, KwaZulu-Natal, 4092, South Africa
SAMRC Isipingo CRS
NOT_YET_RECRUITING

Durban, KwaZulu-Natal, 4110, South Africa
Synergy Biomed Research Institute
NOT_YET_RECRUITING

Durban, Eastern Cape, 5201, South Africa
Wits Vaccines & Infectious Diseases Analytics (VIDA) Research Unit
NOT_YET_RECRUITING

Johannesburg, Gauteng, 1862, South Africa

More trials for these conditions

Other studies related to the condition(s) this trial covers.